Select Page

MyPeBS
is an international

EU-funded clinical study
that evaluates a new breast cancer screening strategy

9
4
5

Women
included in
the study so far

What is MyPeBS ?

MyPeBS (My Personal Breast Screening) is a major ambitious European initiative. This unique international clinical study compares a personalised risk-based screening strategy (based on the individual women’s risk of developing breast cancer) to standard screening among 85,000 women aged 40 to 70 in 6 countries: Belgium, France, Israel, Italy, United Kingdom and Spain.

MyPeBS (My Personal Breast Screening) is a major ambitious European initiative. This unique international clinical study compares a personalised risk-based screening strategy (based on the individual women’s risk of developing breast cancer) to standard screening among 85,000 women aged 40 to 70 in 6 countries: Belgium, France, Israel, Italy, United Kingdom and Spain.

Animation video presenting the MyPeBS study

News

MAP 2021

MAP 2021

Come (virtually) and listen to Fiona Gilbert (University of Cambridge, UK) and Gareth Evans (Manchester University, UK) talk about early detection of cancer at the MAP (Molecular Analysis for Precision Oncology) 2021 virtual congress! The “early detection” session is...

read more
Already 10,000 women participating in MyPeBS!

Already 10,000 women participating in MyPeBS!

Breast cancer: better screening for better care Already 10,000 women participating in MyPeBS! May, 2021 – Unicancer announces the inclusion of 10,000 female volunteers in the MyPeBS (My Personal Breast cancer Screening) study, almost half of whom were recruited in...

read more

Partners

Members of the MyPeBS Consortium
Associated partners
Members of the MyPeBS Consortium
Members of the MyPeBS Consortium
Associated partners
Members of the MyPeBS Consortium
Members of the MyPeBS Consortium

Members of the MyPeBS Consortium
Associated partners

Members of the MyPeBS Consortium
Members of the MyPeBS Consortium

The MyPeBS study is supported by the French Health Insurance and the French National Cancer Institute (INCa), and has been approved by the Cancer Screening Strategic Committee chaired by the French General Director of Health.